Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex

NCT02634931 is registered in ClinicalTrials.gov with Nobelpharma as lead sponsor.

NCT NCT02634931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02634931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
Lead sponsor
Nobelpharma
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2015
Completion date
October 31, 2018
Enrollment
94 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angiofibroma, hypomelanotic macule, plaque, tuberous sclerosis